Alchemia Strengthens VAST(TM) R&D with the Establishment of an International Scientific Advisory Board
BRISBANE, Australia--(BUSINESS WIRE)--Alchemia Limited (ASX:ACL) today announced the establishment of a Scientific Advisory Board (SAB) comprising several international experts, with significant research and commercialisation experience, to guide the development of Alchemia’s VASTTM drug discovery platform.
Peter Smith, CEO of Alchemia, said he was delighted that Alchemia had successfully attracted a team of this caliber. The SAB includes internationally renowned experts in the fields of GPCR pharmacology, toxicology, drug design and development, medicinal chemistry and molecular diversity, all of which are necessary for the successful development and commercialization of Alchemia’s drug discovery platform, VASTTM.